JP2022553833A - エストロゲン受容体調節薬の塩及び形態 - Google Patents

エストロゲン受容体調節薬の塩及び形態 Download PDF

Info

Publication number
JP2022553833A
JP2022553833A JP2022525923A JP2022525923A JP2022553833A JP 2022553833 A JP2022553833 A JP 2022553833A JP 2022525923 A JP2022525923 A JP 2022525923A JP 2022525923 A JP2022525923 A JP 2022525923A JP 2022553833 A JP2022553833 A JP 2022553833A
Authority
JP
Japan
Prior art keywords
degrees
theta
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553833A5 (https=
Inventor
キンファ ファン，ピーター
ガジャナン ヘグデ，サイー
デュアン バンカー，ケビン
ナイト，ジョン
ヘレン スリー，デボラ
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2022553833A publication Critical patent/JP2022553833A/ja
Publication of JP2022553833A5 publication Critical patent/JP2022553833A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022525923A 2019-11-04 2020-11-02 エストロゲン受容体調節薬の塩及び形態 Pending JP2022553833A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930153P 2019-11-04 2019-11-04
US62/930,153 2019-11-04
PCT/US2020/058526 WO2021091819A1 (en) 2019-11-04 2020-11-02 Salts and forms of an estrogen receptor modulator

Publications (2)

Publication Number Publication Date
JP2022553833A true JP2022553833A (ja) 2022-12-26
JP2022553833A5 JP2022553833A5 (https=) 2023-11-13

Family

ID=75849360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525923A Pending JP2022553833A (ja) 2019-11-04 2020-11-02 エストロゲン受容体調節薬の塩及び形態

Country Status (12)

Country Link
US (1) US20220389006A1 (https=)
EP (1) EP4045507A4 (https=)
JP (1) JP2022553833A (https=)
KR (1) KR20220103977A (https=)
CN (1) CN114945570A (https=)
AU (1) AU2020380211A1 (https=)
BR (1) BR112022008520A2 (https=)
CA (1) CA3159749A1 (https=)
IL (1) IL292680A (https=)
MX (1) MX2022005139A (https=)
TW (1) TW202132294A (https=)
WO (1) WO2021091819A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) * 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515026A (ja) * 2016-04-01 2019-06-06 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201028414A (en) * 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
WO2021216671A1 (en) * 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515026A (ja) * 2016-04-01 2019-06-06 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0005557793 *
浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0005557795 *
長瀬博監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), pages 347 - 365, ISSN: 0005557792 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005557794 *

Also Published As

Publication number Publication date
TW202132294A (zh) 2021-09-01
EP4045507A4 (en) 2023-11-01
MX2022005139A (es) 2022-06-24
CN114945570A (zh) 2022-08-26
AU2020380211A1 (en) 2022-05-19
CA3159749A1 (en) 2021-05-14
US20220389006A1 (en) 2022-12-08
IL292680A (en) 2022-07-01
BR112022008520A2 (pt) 2022-07-26
WO2021091819A1 (en) 2021-05-14
EP4045507A1 (en) 2022-08-24
KR20220103977A (ko) 2022-07-25

Similar Documents

Publication Publication Date Title
JP7035108B2 (ja) プリドピジンの類似体、それらの製造および使用
JP2023533040A (ja) Ｗｅｅ１阻害剤の塩及び形態
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
US11560369B2 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
CN104736526A (zh) 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
JP2022553833A (ja) エストロゲン受容体調節薬の塩及び形態
CN108727347A (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN102803247B (zh) 组胺h3受体拮抗剂的新颖富马酸盐
CA2701638A1 (en) Pharmaceutical calcimimetics
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
TW201904954A (zh) 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法
TW201815793A (zh) 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
WO2010040315A1 (zh) 1-丁基-2-羟基芳烷哌嗪衍生物及作为抗抑郁剂的应用
WO2023059610A1 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US12030886B2 (en) Form of ponatinib
JP7705351B2 (ja) ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形
WO2004031125A1 (ja) スピロ化合物、それを含有する医薬組成物及び該化合物の中間体
TWI267511B (en) Process for preparing 10,11-methanobenzosuberane derivatives
WO2021150700A1 (en) N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
CN116751186B (zh) 一种雌激素受体调节剂的制备及其用途
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
EP3418270A1 (en) Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
CN106397413B (zh) 5-羟色胺受体激动剂及其制备方法和用途
WO2024235167A1 (zh) 一种吡唑并吡嗪类化合物及其晶型的制备方法
CN116082302A (zh) 氘代吲唑-吡啶-苯基-三氟乙基四取代烯烃类化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250325